DOES AZILSARTAN MEDOXIMIL – CHLORTHALIDONE LOWER RISK OF CORONARY HEART DISEASE THAN OLMESARTAN MEDOXIMIL – HYDROCHLORTHIAZIDE IN PATIENTS WITH ESSENTIAL HYPERTENSION- A COST-EFFECTIVE ANALYSIS
Author(s)
Bhansali A1, Sansgiry SS2
1University of Houston College of Pharmacy, Houston, TX, USA, 2University of Houston, Houston, TX, USA
Presentation Documents
OBJECTIVES: The study objective was to investigate and compare the relative costs and effects of using azilsartan medoximil – chlorthalidone, a newly approved combination therapy in comparison to existing olmesartan medoximil – hydrochlorthiazide in treating mild to moderate essential hypertension, using the third party payer perspective and the risk of developing coronary heart disease (CHD) in 10 years. METHODS: : A decision tree analysis was done using Tree Age Pro®
Conference/Value in Health Info
2015-05, ISPOR 2015, Philadelphia, PA, USA
Value in Health, Vol. 18, No. 3 (May 2015)
Code
PCV79
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies, Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
Cardiovascular Disorders